Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Subbiah, Vivek ^a,b   Meric Bernstam, Funda ^a,b   Mills, Gordon B ^b   Shaw, Kenna R Mills ^b   Bailey, Ann Marie ^b   Rao, Priya ^b   Ward, John F ^b   Pagliaro, Lance C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Adolescent and young adult; EGFR; Exceptional responder; Germ cell tumor; Next generation sequencing; Outlier responder; Phase II trials; RET; Sunitinib; Targeted therapy; Unusual responder; Vascular endothelial growth factor receptor; VEGF

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CD30 ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKERATIN; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; LEVOTHYROXINE; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PLATINUM DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN RET; PYRROLE DERIVATIVE; RET PROTEIN, HUMAN;

ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ADOLESCENT; ADULT; ADVANCED CANCER; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BONE BIOPSY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG SENSITIVITY; EGFR GENE; FOLLOW UP; GENE AMPLIFICATION; GENE SEQUENCE; GERM CELL TUMOR; HISTOPATHOLOGY; HOSPICE CARE; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; LUNG NODULE; LYMPH NODE DISSECTION; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEXT GENERATION SEQUENCING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; ONCOGENE K RAS; ONCOGENE RET; ORCHIECTOMY; PHASE 2 CLINICAL TRIAL; PTEN GENE; SEQUENCE ANALYSIS; TREATMENT RESPONSE; YOUNG ADULT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; HIGH THROUGHPUT SEQUENCING; MEDIASTINAL NEOPLASMS; MORTALITY; NEOPLASMS, GERM CELL AND EMBRYONAL; RETROPERITONEAL NEOPLASMS; TESTICULAR NEOPLASMS;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDOLES; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PLATINUM COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; PYRROLES; RETROPERITONEAL NEOPLASMS; TESTICULAR NEOPLASMS; YOUNG ADULT;

EID: 84908288657     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-014-0052-x     Document Type: Article

References (50)

1. Chemotherapy for advanced germ cell tumors. GV Kondagunta, RJ Motzer, J Clin Oncol 2006 24 35 5493 5502 17158534
2. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). HJ Schmoll, R Souchon, S Krege, P Albers, J Beyer, C Kollmannsberger, SD Fossa, NE Skakkebaek, R de Wit, K Fizazi, JP Droz, G Pizzocaro, G Daugaard, PH de Mulder, A Horwich, T Oliver, R Huddart, G Rosti, L Paz Ares, O Pont, JT Hartmann, N Aass, F Algaba, M Bamberg, I Bodrogi, C Bokemeyer, J Classen, S Clemm, S Culine, M de Wit, et al. Ann Oncol 2004 15 9 1377 1399 15319245
3. Management of recurrent testicular germ cell tumors. G Sonpavde, TE Hutson, BJ Roth, Oncologist 2007 12 1 51 61 17227900
4. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. C Kollmannsberger, C Nichols, C Bokemeyer, Cancer 2006 106 6 1217 1226 16463389
5. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. S Fukuda, T Shirahama, Y Imazono, T Tsushima, H Ohmori, T Kayajima, S Take, K Nishiyama, S Yonezawa, S Akiba, S Akiyama, Y Ohi, Cancer 1999 85 6 1323 1330 10189138
6. Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors. O Arrieta, RM Michel Ortega, J Angeles-Sanchez, C Villarreal-Garza, A Aviles-Salas, JG Chanona-Vilchis, E Arechaga-Ocampo, A Luevano-Gonzalez, MA Jimenez, JL Aguilar, J Exp Clin Cancer Res 2009 28 120 19709439
7. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. G Viglietto, A Romano, D Maglione, M Rambaldi, I Paoletti, Lago, D Califano, C Monaco, A Mineo, G Santelli, G Manzo, G Botti, G Chiappetta, MG Persico, Oncogene 1996 13 3 577 587 8760299
8. Sunitinib: from rational design to clinical efficacy. LQ Chow, SG Eckhardt, J Clin Oncol 2007 25 7 884 896 17327610
9. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. P Therasse, SG Arbuck, EA Eisenhauer, J Wanders, RS Kaplan, L Rubinstein, J Verweij, M Van Glabbeke, AT van Oosterom, MC Christian, SG Gwyther, J Natl Cancer Inst 2000 92 3 205 216 10655437
10. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). EA Eisenhauer, P Therasse, J Bogaerts, LH Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney, L Rubinstein, L Shankar, L Dodd, R Kaplan, D Lacombe, J Verweij, Eur J Cancer 2009 45 2 228 247 19097774
11. Fast and accurate short read alignment with Burrows-Wheeler transform. H Li, R Durbin, Bioinformatics 2009 25 14 1754 1760 19451168
12. A framework for variation discovery and genotyping using next-generation DNA sequencing data. MA DePristo, E Banks, R Poplin, KV Garimella, JR Maguire, C Hartl, AA Philippakis, G del Angel, MA Rivas, M Hanna, A McKenna, TJ Fennell, AM Kernytsky, AY Sivachenko, K Cibulskis, SB Gabriel, D Altshuler, MJ Daly, Nat Genet 2011 43 5 491 498 21478889
13. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. RJ Lonigro, CS Grasso, DR Robinson, X Jing, YM Wu, X Cao, MJ Quist, SA Tomlins, KJ Pienta, AM Chinnaiyan, Neoplasia 2011 13 11 1019 1025 22131877
14. Molecular inversion probes: a novel microarray technology and its application in cancer research. Y Wang, M Cottman, JD Schiffman, Cancer Genet 2012 205 7-8 341 355 22867995
15. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. BI Rini, I Tamaskar, P Shaheen, R Salas, J Garcia, L Wood, S Reddy, R Dreicer, RM Bukowski, J Natl Cancer Inst 2007 99 1 81 83 17202116
16. Building a personalized medicine infrastructure at a major cancer center. F Meric-Bernstam, C Farhangfar, J Mendelsohn, GB Mills, J Clin Oncol 2013 31 15 1849 1857 23589548
17. RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high-grade malignancy. M Nakashima, N Takamura, H Namba, V Saenko, S Meirmanov, N Matsumoto, T Hayashi, S Maeda, I Sekine, Hum Pathol 2007 38 4 621 628 17270245
18. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. RM Melillo, MD Castellone, V Guarino, V De Falco, AM Cirafici, G Salvatore, F Caiazzo, F Basolo, R Giannini, M Kruhoffer, T Orntoft, A Fusco, M Santoro, J Clin Investig 2005 115 4 1068 1081 15761501
19. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. SJ Jones, J Laskin, YY Li, OL Griffith, J An, M Bilenky, YS Butterfield, T Cezard, E Chuah, R Corbett, AP Fejes, M Griffith, J Yee, M Martin, M Mayo, N Melnyk, RD Morin, TJ Pugh, T Severson, SP Shah, M Sutcliffe, A Tam, J Terry, N Thiessen, T Thomson, R Varhol, T Zeng, Y Zhao, RA Moore, DG Huntsman, et al. Genome Biol 2010 11 8 82 20696054
20. A case of advanced medullary thyroid carcinoma successfully treated with sunitinib. MJ Bugalho, R Domingues, A Borges, Oncologist 2009 14 11 1083 1087 19887470
21. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. DW Kim, YS Jo, HS Jung, HK Chung, JH Song, KC Park, SH Park, JH Hwang, SY Rha, GR Kweon, SJ Lee, KW Jo, M Shong, J Clin Endocrinol Metab 2006 91 10 4070 4076 16849418
22. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation. WJ Jeong, JH Mo, MW Park, IJ Choi, SY An, EH Jeon, SH Ahn, Cancer Biol Ther 2011 12 5 458 465 21725210
23. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. SJ Dawson, NM Conus, GC Toner, JM Raleigh, RJ Hicks, G McArthur, D Rischin, Anti-Cancer Drugs 2008 19 5 547 552 18418222
24. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. AD Joshi, W Loilome, IM Siu, B Tyler, GL Gallia, GJ Riggins, PLoS ONE 2012 7 10 44372 23056179
25. Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation. F Pan, J Tian, X Zhang, Y Zhang, Y Pan, J Cancer Res Clin Oncol 2011 137 9 1397 1408 21796416
26. Ras gene amplification and malignant transformation. S Pulciani, E Santos, LK Long, V Sorrentino, M Barbacid, Mol Cell Biol 1985 5 10 2836 2841 3915535
27. Characterizing the cancer genome in lung adenocarcinoma. BA Weir, MS Woo, G Getz, S Perner, L Ding, R Beroukhim, WM Lin, MA Province, A Kraja, LA Johnson, K Shah, M Sato, RK Thomas, JA Barletta, IB Borecki, S Broderick, AC Chang, DY Chiang, LR Chirieac, J Cho, Y Fujii, AF Gazdar, T Giordano, H Greulich, M Hanna, BE Johnson, MG Kris, A Lash, L Lin, N Lindeman, et al. Nature 2007 450 7171 893 898 17982442
28. Amplification of protooncogenes in surgical specimens of human lung carcinomas. M Shiraishi, M Noguchi, Y Shimosato, T Sekiya, Cancer Res 1989 49 23 6474 6479 2573414
29. In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma. PL Wagner, S Perner, DS Rickman, CJ LaFargue, N Kitabayashi, SF Johnstone, BA Weir, M Meyerson, NK Altorki, MA Rubin, Am J Clin Pathol 2009 132 4 500 505 19762526
30. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. A Piscazzi, E Costantino, F Maddalena, MI Natalicchio, AM Gerardi, R Antonetti, M Cignarelli, M Landriscina, J Clin Endocrinol Metab 2012 97 6 898 E906 22442268
31. Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. L Gandhi, KL McNamara, D Li, CL Borgman, U McDermott, KA Brandstetter, RF Padera, LR Chirieac, JE Settleman, KK Wong, Cancer Prev Res (Phila) 2009 2 4 330 337
32. The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma. R D'Amico, L Lei, BC Kennedy, J Sisti, V Ebiana, C Crisman, JG Christensen, O Gil, SS Rosenfeld, P Canoll, JN Bruce, Neurol Res 2012 34 3 252 261 22449730
33. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. F Yang, V Jove, H Xin, M Hedvat, TE Van Meter, H Yu, Mol Cancer Res 2010 8 1 35 45 20053726
34. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. T Ikezoe, Y Yang, C Nishioka, K Bandobashi, H Nakatani, T Taguchi, HP Koeffler, H Taguchi, Cancer Sci 2006 97 9 945 951 16916320
35. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. W Fiedler, H Serve, H Dohner, M Schwittay, OG Ottmann, AM O'Farrell, CL Bello, R Allred, WC Manning, JM Cherrington, SG Louie, W Hong, NM Brega, G Massimini, P Scigalla, WE Berdel, DK Hossfeld, Blood 2005 105 3 986 993 15459012
36. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. P Albers, R Siener, S Kliesch, L Weissbach, S Krege, C Sparwasser, H Schulze, A Heidenreich, W de Riese, V Loy, E Bierhoff, C Wittekind, R Fimmers, M Hartmann, J Clin Oncol 2003 21 8 1505 1512 12697874
37. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. W Castillo-Avila, JM Piulats, X Garcia Del Muro, A Vidal, E Condom, O Casanovas, J Mora, JR Germa, G Capella, A Villanueva, F Vinals, Clin Cancer Res 2009 15 10 3384 3395 19417025
38. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. DR Feldman, S Turkula, MS Ginsberg, N Ishill, S Patil, M Carousso, GJ Bosl, RJ Motzer, Invest New Drugs 2010 28 4 523 528 19547919
39. The PDGFRbeta-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. M Juliachs, C Munoz, CA Moutinho, A Vidal, E Condom, M Esteller, M Graupera, O Casanovas, JR Germa, A Villanueva, F Vinals, Clin Cancer Res 2014 20 3 658 667 24277456
40. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. K Oechsle, F Honecker, T Cheng, F Mayer, P Czaykowski, E Winquist, L Wood, M Fenner, S Glaesener, JT Hartmann, K Chi, C Bokemeyer, C Kollmannsberger, Ann Oncol 2011 22 12 2654 2660 21415240
41. Final report of the first refractory germ cell tumor treated with Sunitinib Malate. JM Gasent Blesa, E Grande Pulido, J Laforga Canales, V Alberola Candel, Case Rep Oncol 2009 2 3 234 241 20737043
42. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. LH Einhorn, MJ Brames, MC Heinrich, CL Corless, A Madani, Am J Clin Oncol 2006 29 1 12 13 16462496
43. Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma. D Pectasides, M Nikolaou, E Pectasides, A Koumarianou, C Valavanis, T Economopoulos, Anticancer Res 2008 28 4C 2317 2320 18751412
44. Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. R Pedersini, E Vattemi, G Mazzoleni, C Graiff, Lancet Oncol 2007 8 11 1039 1040 17976614
45. Targeted therapies for patients with germ cell tumors. MH Fenner, G Beutel, V Grunwald, Expert Opin Investig Drugs 2008 17 4 511 522 18363516
46. Third-line chemotherapy and novel agents for metastatic germ cell tumors. CM Veenstra, DJ Vaughn, Hematol Oncol Clin North Am 2011 25 3 577 591 ix 21570610
47. Treatment of growing teratoma syndrome. DJ Vaughn, K Flaherty, P Lal, M Gallagher, P O'Dwyer, K Wilner, I Chen, G Schwartz, N Engl J Med 2009 360 4 423 424 19164198
48. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. S Kummar, HX Chen, J Wright, S Holbeck, MD Millin, J Tomaszewski, J Zweibel, J Collins, JH Doroshow, Nat Rev Drug Discov 2011 9 11 843 856
49. Late relapse of germ cell tumors after cisplatin-based chemotherapy. A Gerl, C Clemm, N Schmeller, M Hentrich, R Lamerz, W Wilmanns, Ann Oncol 1997 8 1 41 47 9093706
50. Late relapse of testicular cancer. J Baniel, RS Foster, R Gonin, JE Messemer, JP Donohue, LH Einhorn, J Clin Oncol 1995 13 5 1170 1176 7537800